Trevi Therapeutics Inc (TRVI)


Stock Price Forecast

March 18, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Trevi Therapeutics Inc chart...

About the Company

trevi therapeutics, inc. is a late-stage biopharmaceutical company focused on developing nalbuphine® er for chronic pruritic conditions. pruritus develops in various dermatologic, metabolic, hematologic and neuropathic conditions. the company is pursuing several pruritic conditions for clinical development, including its lead indication of prurigo nodularis. prurigo nodularis is a chronic pruritic dermatologic condition characterized by the presence of pruriginous lesions (excoriative/ulcerative papules and nodules) on the skin. there are no approved therapies in the us or eu for this condition. nalbuphine® er is an oral extended release synthetic opioid with a dual mechanism of action, mu receptor antagonist and kappa receptor agonist, both of which have been shown in research to be effective in abolishing itch. because of nalbuphine® er’s unique dual mechanism of action, which has shown efficacy in addressing pruritus in human clinical trials, the company believes nalbuphine® er can

Exchange

NASDAQ

Website

trevitherapeutics.com

$M

Total Revenue

26

Employees

$208M

Market Capitalization

-10.34

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $TRVI News

Mizuho downgrades Amylyx to Neutral after ALS trial setback

on MSN ago, source:

Mizuho has lowered its recommendation on Amylyx ( NASDAQ: AMLX ), downgrading it from Buy to Neutral while cutting its 12-month price target to $4 from $32. The downgrade comes after the company ...

Jefferies starts Viking Therapeutics at buy, cites "scarcity value"

11d ago, source: Seeking Alpha on MSN

Jefferies initiated coverage of Viking Therapeutics (NASDAQ:VKTX) with a buy rating, noting that the weight-loss drug ...

VTv Therapeutics: Q4 Earnings Snapshot

6d ago, source: SFGate

HIGH POINT, N.C. (AP) — HIGH POINT, N.C. (AP) — VTv Therapeutics Inc. (VTVT) on Wednesday reported a loss of $3.5 million in its fourth quarter. The High Point, North Carolina-based company said it ...

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

5d ago, source:

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on March 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 51,600 ...

One million Euro gets thrown into Rome’s Trevi Fountain each year. What happens next?

11d ago, source: Inquirer on MSN

In 2022 Caritas collected 1.4 million euros ($1.52 million) from the fountain and it expects to have gathered even more in ...

Gloria Trevi Lights Up New York, Debuts ‘Zorra' Remix With Nebulossa

on MSN ago, source:

The Mexican icon journeys through three decades of hits on her Mi Soundtrack tour at a sold-out Radio City Music Hall.

What happens to the coins tossed into Rome's Trevi Fountain?

11d ago, source:

As visitors' coins splash into Rome's majestic Trevi Fountain carrying wishes for love, good health or a return to the ...

Make a wish: The fate of coins tossed in Rome's Trevi Fountain

11d ago, source: Daily Sabah

Rome's famous Trevi Fountain has witnessed wishes for eternal love, fast fortunes, miracle cures and so much more as tourists ...

Vista Shaw, The Spectrum, Wil Tower, and Laureano di Trevi Towers unveil big-cut units

5d ago, source: BusinessWorld

Vista Land’s Vista Shaw, The Spectrum, Wil Tower, and Laureano di Trevi Towers—recently unveiled their big-cut units at an exclusive event called  “Plethora,” which was held at the Brittany Hotel in ...

Visitors' coins in Rome's Trevi Fountain provide practical help to Italians

11d ago, source:

For hundreds of years, when in Rome, visitors have flocked to the fountain to make a wish, following a storied ritual. Few ...

Buy Rating Affirmed for Verve Therapeutics Amidst Promising Clinical Studies and Strategic Advancements

19d ago, source:

Analyst Cory Jubinville, PhD of LifeSci Capital maintained a Buy rating on Verve Therapeutics (VERV – Research Report), with a price ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...